AVI 2221

Drug Profile

AVI 2221

Latest Information Update: 05 Jun 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AVI BioPharma
  • Developer AVI BioPharma; Depomed; Interventional Technologies; MDS Pharma Services
  • Class Ischaemic heart disorder therapies
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Coronary artery restenosis

Most Recent Events

  • 05 Jun 2001 Discontinued-Preclincal for Coronary artery restenosis in USA (PO)
  • 05 Jun 2001 Discontinued-Preclinical for Cancer in USA (Parenteral)
  • 05 Jun 2001 Discontinued-Preclinical for Coronary artery restenosis in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top